Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: New Appointments at Verily, 23andMe, Resolve Biosciences, More

Verily: Amy Abernethy

Verily has appointed Amy Abernethy as president of its clinical research business. Abernethy was most recently principal deputy commissioner of food and drugs and acting chief information officer at the US Food and Drug Administration. Prior to her role at FDA, Abernethy was chief medical officer, chief scientific officer, and senior vice president of Flatiron Health, now part of Roche. Abernethy has also been a professor of medicine at Duke University School of Medicine; director of the Center for Learning Health Care in the Duke Clinical Research Institute; and director of the Duke Cancer Care Research Program in the Duke Cancer Institute.


23andMe: Wade Walke

Wade Walke has joined 23andMe as VP of investor relations. Previously, he held the same title at Ionis Pharmaceuticals, and before that, he held various positions at Lexicon Pharmaceuticals, including associate director of bioinformatics in the department of functional genomics and head of communications and investor relations. Walke holds a BSc from Brigham Young University as well as PhD and MSc degrees from the University of Michigan.


Resolve Biosciences: Chris Barbazette

Resolve Biosciences has appointed Chris Barbazette as chief commercial officer. He will lead the firm's growing sales and marketing operations. Prior to this, he was senior VP of global sales and support at GenapSys. He has also held executive positions at Agendia and Affymetrix.


For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.